Volume | 108,175 |
|
|||||
News | - | ||||||
Day High | 1.94 | Low High |
|||||
Day Low | 1.80 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
eFFECTOR Therapeutics Inc | EFTR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.90 | 1.80 | 1.94 | 1.85 | 1.94 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
678 | 108,175 | $ 1.87 | $ 201,998 | - | 1.60 - 37.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:25:56 | 10 | $ 1.87 | USD |
eFFECTOR Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.54M | 3.00M | - | 0 | -35.81M | -11.95 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
eFFECTOR Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EFTR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.01 | 2.05 | 1.60 | 1.81 | 161,204 | -0.22 | -10.95% |
1 Month | 12.82 | 16.882 | 1.60 | 3.55 | 881,952 | -11.03 | -86.04% |
3 Months | 10.79 | 17.75 | 1.60 | 6.10 | 396,405 | -9.00 | -83.41% |
6 Months | 14.00 | 17.90 | 1.60 | 11.69 | 1,235,761 | -12.21 | -87.21% |
1 Year | 10.50 | 37.00 | 1.60 | 16.56 | 1,266,347 | -8.71 | -82.95% |
3 Years | 475.00 | 1,010.50 | 1.60 | 117.58 | 792,561 | -473.21 | -99.62% |
5 Years | 475.00 | 1,010.50 | 1.60 | 117.58 | 792,561 | -473.21 | -99.62% |
eFFECTOR Therapeutics Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California. |